EGFR signaling in liver diseases
K Komposch, M Sibilia - International journal of molecular sciences, 2015 - mdpi.com
The epidermal growth factor receptor (EGFR) is a transmembrane receptor tyrosine kinase
that is activated by several ligands leading to the activation of diverse signaling pathways …
that is activated by several ligands leading to the activation of diverse signaling pathways …
Genomics and signaling pathways in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a leading cause of death among cirrhotic patients and
has become a major health problem in developed countries. There is an elemental …
has become a major health problem in developed countries. There is an elemental …
Rethink of EGFR in cancer with its kinase independent function on board
R Thomas, Z Weihua - Frontiers in oncology, 2019 - frontiersin.org
The epidermal growth factor receptor (EGFR) is one of most potent oncogenes that are
commonly altered in cancers. As a receptor tyrosine kinase, EGFR's kinase activity has been …
commonly altered in cancers. As a receptor tyrosine kinase, EGFR's kinase activity has been …
Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents …
BACKGROUND/AIMS: FGFR4, a member of the fibroblast growth factor receptor family, has
been recently associated with progression of melanoma, breast and head and neck …
been recently associated with progression of melanoma, breast and head and neck …
[HTML][HTML] Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations
Epidermal growth factor receptor (EGFR) is one of the most commonly altered genes in
human cancer by way of over-expression, amplification, and mutation. Targeted inhibition of …
human cancer by way of over-expression, amplification, and mutation. Targeted inhibition of …
[HTML][HTML] Anti-EGFR therapies in nasopharyngeal carcinoma
X Chen, R Liang, X Zhu - Biomedicine & Pharmacotherapy, 2020 - Elsevier
Nasopharyngeal carcinoma (NPC) is a common malignant tumor in Southern China and
South-East Asia. Regardless of initiative high response to radiotherapy, parts of patients still …
South-East Asia. Regardless of initiative high response to radiotherapy, parts of patients still …
HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib
Purpose: Biliary cancers (BCs) respond poorly to chemotherapy. Lapatinib is a dual inhibitor
of epidermal growth factor receptor (EGFR) and HER2/neu, both implicated in …
of epidermal growth factor receptor (EGFR) and HER2/neu, both implicated in …
Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions
Systemic therapy is an integral part of the management of non‐keratinizing nasopharyngeal
carcinoma (NPC). The purposes of this review are to provide the latest results and future …
carcinoma (NPC). The purposes of this review are to provide the latest results and future …
SPINK6 promotes metastasis of nasopharyngeal carcinoma via binding and activation of epithelial growth factor receptor
LS Zheng, JP Yang, Y Cao, LX Peng, R Sun, P Xie… - Cancer research, 2017 - AACR
Nasopharyngeal carcinoma has the highest rate of metastasis among head and neck
cancers, and distant metastasis is the major reason for treatment failure. The underlying …
cancers, and distant metastasis is the major reason for treatment failure. The underlying …
HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant
N Sueangoen, A Tantiwetrueangdet, R Panvichian - Cell & Bioscience, 2020 - Springer
Background Epidermal growth factor receptor (EGFR) has emerged as an important
therapeutic target. Overexpression of EGFR is frequently observed in hepatocellular …
therapeutic target. Overexpression of EGFR is frequently observed in hepatocellular …